Data / Public companies / New York / Biological products, (no diagnostic substances)
Biological products, (no diagnostic substances) companies in New York: 9 that file annual reports with the SEC
Updated September 30, 2026. Source: SEC Financial Statement Data Sets (sec.gov).
9 companies that file annual reports with the SEC have a business address in New York and the industry code SIC 2836 (Biological products, (no diagnostic substances)), in the SEC Financial Statement Data Sets filed through September 30, 2026. 1 report revenue, a combined $81.4 million. 0.0% of the 9 that report net income show a profit. The largest by revenue is Meiragtx Holdings PLC ($81.4 million).
The request: Get every company that files with the SEC in New York in the industry Biological products, (no diagnostic substances) (SIC 2836), with its revenue, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- 2836SIC code
- 9Companies with an annual report in the data
- 1Companies that report revenue
- $81.4 millionCombined revenue
- $81.4 millionMedian revenue
- 0 of 9 (0.0%)Reported a net profit
- $923.4 millionCombined total assets
- 1Large accelerated filers
- April 15, 2026Newest annual report filed
Largest by revenue
Latest fiscal year, from each company's annual report. Each name links to the company's page.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Meiragtx Holdings PLC | New York, NY | $81.4 million | $-114,201,000 | $244.4 million | 144.6% |
Cities with the most companies
By city of the business address.
| City | Companies | Share |
|---|---|---|
| New York | 8 | 88.9% |
| Purchase | 1 | 11.1% |
Newest annual reports
By the date the company filed its latest annual report with the SEC.
| Company | Filed | Fiscal year ended | Form | Revenue |
|---|---|---|---|---|
| Abpro Holdings, Inc. | April 15, 2026 | December 31, 2025 | 10-K | Not listed |
| Mink Therapeutics, Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Brainstorm Cell Therapeutics Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Lexeo Therapeutics, Inc. | March 30, 2026 | December 31, 2025 | 10-K | Not listed |
| Meiragtx Holdings PLC | March 30, 2026 | December 31, 2025 | 10-K | $81.4 million |
| Cognition Therapeutics Inc | March 26, 2026 | December 31, 2025 | 10-K | Not listed |
| In8bio, Inc. | March 12, 2026 | December 31, 2025 | 10-K | Not listed |
| Protara Therapeutics, Inc. | March 10, 2026 | December 31, 2025 | 10-K | Not listed |
| Anavex Life Sciences Corp. | November 25, 2025 | September 30, 2025 | 10-K | Not listed |
Filer category
The SEC's size class for the company when it filed.
| Category | Companies | Share |
|---|---|---|
| Non-accelerated filer | 8 | 88.9% |
| Large accelerated filer | 1 | 11.1% |
Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.